Predictive Toxicology: Organ-Chips Demonstrate Superior Performance To Animal Models And Spheroids

This webinar is based on data from a bioRxiv preprint and features the final paper, “Performance Assessment and Economic Analysis of a Human Liver-Chip for Predictive Toxicology,” now published in Communications Medicine, part of the Nature Portfolio.

To gain insights from the authors on how these findings could influence future research and drug development, watch our webinar titled “Towards A More Predictive Model of Human Biology: A Fireside Chat.”

Late-stage drug development failures are a significant challenge in the pharmaceutical industry. Human organ-on-a-chip (Organ-Chip) technology has the potential to revolutionize preclinical drug discovery by accurately replicating organ-level pathophysiology and clinical responses. While industrial guidelines outline criteria for qualifying preclinical models, a systematic and quantitative evaluation of Organ-Chips' predictive value has yet to be conducted.

In this webinar, we examine how 780 human Liver-Chips were assessed for their ability to predict drug-induced liver injury from small molecules. The Liver-Chip showed an impressive 87% sensitivity and 100% specificity across a blinded set of 27 known hepatotoxic and non-toxic drugs. Economic analysis indicates that, with such performance, the Liver-Chip could potentially generate $3 billion annually in small-molecule drug development by enhancing research and development productivity.

Join us to learn about:

• The impact of more predictive preclinical models on clinical success and productivity
• How the Emulate Liver-Chip performs against IQ MPS guidelines
• Comparisons of the Emulate Liver-Chip with animal models and hepatic spheroids
• The economic potential of incorporating the Liver-Chip into routine small-molecule liver toxicity testing
• Implementation strategies for the Emulate Liver-Chip in the drug development process